JP2022526553A5 - - Google Patents

Info

Publication number
JP2022526553A5
JP2022526553A5 JP2021557759A JP2021557759A JP2022526553A5 JP 2022526553 A5 JP2022526553 A5 JP 2022526553A5 JP 2021557759 A JP2021557759 A JP 2021557759A JP 2021557759 A JP2021557759 A JP 2021557759A JP 2022526553 A5 JP2022526553 A5 JP 2022526553A5
Authority
JP
Japan
Prior art keywords
independently selected
substituted
pharmaceutically acceptable
acceptable salt
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526553A (ja
Filing date
Publication date
Priority claimed from GBGB1904375.1A external-priority patent/GB201904375D0/en
Application filed filed Critical
Publication of JP2022526553A publication Critical patent/JP2022526553A/ja
Publication of JP2022526553A5 publication Critical patent/JP2022526553A5/ja
Pending legal-status Critical Current

Links

JP2021557759A 2019-03-29 2020-03-24 炎症性障害の治療のための新規化合物及びその医薬組成物 Pending JP2022526553A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1904375.1A GB201904375D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB1904375.1 2019-03-29
PCT/EP2020/058061 WO2020200898A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2022526553A JP2022526553A (ja) 2022-05-25
JP2022526553A5 true JP2022526553A5 (cg-RX-API-DMAC7.html) 2023-04-06

Family

ID=66442789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557759A Pending JP2022526553A (ja) 2019-03-29 2020-03-24 炎症性障害の治療のための新規化合物及びその医薬組成物

Country Status (14)

Country Link
US (1) US20220296573A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947374A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022526553A (cg-RX-API-DMAC7.html)
KR (1) KR20210143905A (cg-RX-API-DMAC7.html)
CN (1) CN113677678A (cg-RX-API-DMAC7.html)
AU (1) AU2020252900A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019099A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134732A1 (cg-RX-API-DMAC7.html)
GB (1) GB201904375D0 (cg-RX-API-DMAC7.html)
IL (1) IL286688A (cg-RX-API-DMAC7.html)
MX (1) MX2021011574A (cg-RX-API-DMAC7.html)
PH (1) PH12021552377A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110643YA (cg-RX-API-DMAC7.html)
WO (1) WO2020200898A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7576552B2 (ja) * 2019-01-18 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
WO2023075420A1 (ko) 2021-10-26 2023-05-04 주식회사 엘지에너지솔루션 전극 조립체의 제조방법
WO2023098857A1 (zh) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016928A1 (ja) * 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体
US7566781B2 (en) * 2004-05-10 2009-07-28 Banyu Pharmaceutical Co., Ltd. Imidazopyridine compound
EP2688872A4 (en) * 2011-03-22 2014-08-27 Merck Sharp & Dohme AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES
WO2014139882A1 (en) * 2013-03-14 2014-09-18 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK1231480A1 (zh) * 2014-01-10 2017-12-22 Aurigene Discovery Technologies Limited 作为irak4抑制剂的吲唑化合物
EP3394066A2 (en) * 2015-12-22 2018-10-31 H. Hoffnabb-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
JP7576552B2 (ja) * 2019-01-18 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders

Similar Documents

Publication Publication Date Title
KR102401963B1 (ko) 면역조절제 화합물
RU2348617C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2022023958A5 (cg-RX-API-DMAC7.html)
JP2024167182A5 (cg-RX-API-DMAC7.html)
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2014507455A5 (cg-RX-API-DMAC7.html)
JP2016518385A5 (cg-RX-API-DMAC7.html)
JP2012521994A5 (cg-RX-API-DMAC7.html)
JP2015509535A5 (cg-RX-API-DMAC7.html)
JPH0314028B2 (cg-RX-API-DMAC7.html)
JP2013512277A5 (cg-RX-API-DMAC7.html)
JP2014500870A5 (cg-RX-API-DMAC7.html)
JP2020505440A5 (cg-RX-API-DMAC7.html)
JP2016515545A5 (cg-RX-API-DMAC7.html)
JP2013533883A5 (cg-RX-API-DMAC7.html)
JP2023533203A5 (cg-RX-API-DMAC7.html)
JP2020521766A5 (cg-RX-API-DMAC7.html)
JP2016532669A5 (cg-RX-API-DMAC7.html)
JP7200005B2 (ja) 飽和環縮合ジヒドロピリミジノン又はジヒドロトリアジノン化合物及びその医薬用途
JP2022526364A5 (cg-RX-API-DMAC7.html)
JP2020511536A5 (cg-RX-API-DMAC7.html)
JP2004525183A5 (cg-RX-API-DMAC7.html)
JP2015502371A5 (cg-RX-API-DMAC7.html)
JP2020514270A5 (cg-RX-API-DMAC7.html)
WO2025189008A1 (en) Methods of treating cftr-mediated diseases or disorders